APO RESEARCH · REPORT
Antibody Therapeutics and Blood Antibody Therapeutics
Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.
Product & engineering
Understand the product.
Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.
Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.
Selected research
Industry Research
Antibody Therapeutics and Blood Antibody Therapeutics Industry Research Report 2026
Market perspective
Antibody, also called immunoglobulin, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto antigens in order to remove them from the body. A wide range of substances are regarded by the body as antigens, including disease-causing organisms and toxic materials such as insect venom.
Treatment that uses antibodies to help the body fight cancer, infection, or other diseases. Antibodies are proteins made by the immune system that bind to specific markers on cells or tissues. IgG1 antibodies are a type of antibody made in the laboratory that can be used in diagnosis or treatment. In cancer treatment, IgG1 antibodies may kill cancer cells directly, they may block development of tumor blood vessels, or they may help the immune system kill cancer cells.
The industry's leading producers are Roche, Abbvie and J & J, with revenues of 15.61%, 12.10% and 10.05% in 2019.
Read the full market overview
Report Scope
This report quantifies the global Antibody Therapeutics and Blood Antibody Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Antibody Therapeutics and Blood Antibody Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Antibody Therapeutics and Blood Antibody Therapeutics Market by Company
Roche
Abbvie
Johnson & Johnson
Bristol-Myers Squibb
Novartis
Merck
Alexion Pharmaceuticals
Takeda
Amgen
Biogen
UCB
Eli Lilly and Company
AstraZeneca
Antibody Therapeutics and Blood Antibody Therapeutics Segment by Type
IgG1
IgG4
Others
Antibody Therapeutics and Blood Antibody Therapeutics Segment by Application
Autoimmune
Tumor
Others
Antibody Therapeutics and Blood Antibody Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antibody Therapeutics and Blood Antibody Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Antibody Therapeutics and Blood Antibody Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antibody Therapeutics and Blood Antibody Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Antibody Therapeutics and Blood Antibody Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- IgG1
- IgG4
- Others
Applications
- Autoimmune
- Tumor
- Others
Companies covered
- Roche
- Abbvie
- Johnson & Johnson
- Bristol-Myers Squibb
- Novartis
- Merck
- Alexion Pharmaceuticals
- Takeda
- Amgen
- Biogen
- UCB
- Eli Lilly and Company
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Antibody Therapeutics and Blood Antibody Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 IgG1
- 2.2.3 IgG4
- 2.2.4 Others
- 2.3 Antibody Therapeutics and Blood Antibody Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Autoimmune
- 2.3.3 Tumor
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Antibody Therapeutics and Blood Antibody Therapeutics Breakdown Data by Type
- 3.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Forecasted Market Size by Type (2027-2032)
4 Antibody Therapeutics and Blood Antibody Therapeutics Breakdown Data by Application
- 4.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Perspective (2021-2032)
- 5.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Growth Trends by Region
- 5.2.1 Global Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Antibody Therapeutics and Blood Antibody Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Antibody Therapeutics and Blood Antibody Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Antibody Therapeutics and Blood Antibody Therapeutics Market Dynamics
- 5.3.1 Antibody Therapeutics and Blood Antibody Therapeutics Industry Trends
- 5.3.2 Antibody Therapeutics and Blood Antibody Therapeutics Market Drivers
- 5.3.3 Antibody Therapeutics and Blood Antibody Therapeutics Market Challenges
- 5.3.4 Antibody Therapeutics and Blood Antibody Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Antibody Therapeutics and Blood Antibody Therapeutics Players by Revenue
- 6.1.1 Global Top Antibody Therapeutics and Blood Antibody Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Antibody Therapeutics and Blood Antibody Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Antibody Therapeutics and Blood Antibody Therapeutics Head Office and Area Served
- 6.4 Global Antibody Therapeutics and Blood Antibody Therapeutics Players, Product Type & Application
- 6.5 Global Antibody Therapeutics and Blood Antibody Therapeutics Manufacturers Established Date
- 6.6 Global Antibody Therapeutics and Blood Antibody Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2021-2032)
- 7.2 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2021-2032)
- 8.2 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2021-2032)
- 10.2 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Antibody Therapeutics and Blood Antibody Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Roche
- 12.1.1 Roche Company Information
- 12.1.2 Roche Business Overview
- 12.1.3 Roche Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.1.4 Roche Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.1.5 Roche Recent Developments
- 12.2 Abbvie
- 12.2.1 Abbvie Company Information
- 12.2.2 Abbvie Business Overview
- 12.2.3 Abbvie Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.2.4 Abbvie Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.2.5 Abbvie Recent Developments
- 12.3 Johnson & Johnson
- 12.3.1 Johnson & Johnson Company Information
- 12.3.2 Johnson & Johnson Business Overview
- 12.3.3 Johnson & Johnson Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.3.4 Johnson & Johnson Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.3.5 Johnson & Johnson Recent Developments
- 12.4 Bristol-Myers Squibb
- 12.4.1 Bristol-Myers Squibb Company Information
- 12.4.2 Bristol-Myers Squibb Business Overview
- 12.4.3 Bristol-Myers Squibb Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.4.4 Bristol-Myers Squibb Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.4.5 Bristol-Myers Squibb Recent Developments
- 12.5 Novartis
- 12.5.1 Novartis Company Information
- 12.5.2 Novartis Business Overview
- 12.5.3 Novartis Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.5.4 Novartis Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.5.5 Novartis Recent Developments
- 12.6 Merck
- 12.6.1 Merck Company Information
- 12.6.2 Merck Business Overview
- 12.6.3 Merck Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.6.4 Merck Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.6.5 Merck Recent Developments
- 12.7 Alexion Pharmaceuticals
- 12.7.1 Alexion Pharmaceuticals Company Information
- 12.7.2 Alexion Pharmaceuticals Business Overview
- 12.7.3 Alexion Pharmaceuticals Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.7.4 Alexion Pharmaceuticals Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.7.5 Alexion Pharmaceuticals Recent Developments
- 12.8 Takeda
- 12.8.1 Takeda Company Information
- 12.8.2 Takeda Business Overview
- 12.8.3 Takeda Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.8.4 Takeda Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.8.5 Takeda Recent Developments
- 12.9 Amgen
- 12.9.1 Amgen Company Information
- 12.9.2 Amgen Business Overview
- 12.9.3 Amgen Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.9.4 Amgen Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.9.5 Amgen Recent Developments
- 12.10 Biogen
- 12.10.1 Biogen Company Information
- 12.10.2 Biogen Business Overview
- 12.10.3 Biogen Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.10.4 Biogen Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.10.5 Biogen Recent Developments
- 12.11 UCB
- 12.11.1 UCB Company Information
- 12.11.2 UCB Business Overview
- 12.11.3 UCB Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.11.4 UCB Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.11.5 UCB Recent Developments
- 12.12 Eli Lilly and Company
- 12.12.1 Eli Lilly and Company Company Information
- 12.12.2 Eli Lilly and Company Business Overview
- 12.12.3 Eli Lilly and Company Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.12.4 Eli Lilly and Company Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.12.5 Eli Lilly and Company Recent Developments
- 12.13 AstraZeneca
- 12.13.1 AstraZeneca Company Information
- 12.13.2 AstraZeneca Business Overview
- 12.13.3 AstraZeneca Revenue in Antibody Therapeutics and Blood Antibody Therapeutics Business (2021-2026)
- 12.13.4 AstraZeneca Antibody Therapeutics and Blood Antibody Therapeutics Product Portfolio
- 12.13.5 AstraZeneca Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst